ATE488251T1 - Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen - Google Patents

Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen

Info

Publication number
ATE488251T1
ATE488251T1 AT05815390T AT05815390T ATE488251T1 AT E488251 T1 ATE488251 T1 AT E488251T1 AT 05815390 T AT05815390 T AT 05815390T AT 05815390 T AT05815390 T AT 05815390T AT E488251 T1 ATE488251 T1 AT E488251T1
Authority
AT
Austria
Prior art keywords
diagnosis
treatment
pregnancy complications
pregnancy related
hypertensive disorder
Prior art date
Application number
AT05815390T
Other languages
English (en)
Inventor
S Karumanchi
Vikas Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE488251T1 publication Critical patent/ATE488251T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT05815390T 2004-09-24 2005-09-26 Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen ATE488251T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61317004P 2004-09-24 2004-09-24
PCT/US2005/034483 WO2006034507A2 (en) 2004-09-24 2005-09-26 Methods of diagnosing and treating complications of pregnancy

Publications (1)

Publication Number Publication Date
ATE488251T1 true ATE488251T1 (de) 2010-12-15

Family

ID=36090722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05815390T ATE488251T1 (de) 2004-09-24 2005-09-26 Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen

Country Status (15)

Country Link
US (3) US20060067937A1 (de)
EP (2) EP1804836B1 (de)
JP (3) JP5270161B2 (de)
KR (2) KR101356894B1 (de)
CN (1) CN101065667B (de)
AT (1) ATE488251T1 (de)
AU (1) AU2005286626B2 (de)
BR (1) BRPI0515884A (de)
CA (1) CA2581336C (de)
DE (1) DE602005024850D1 (de)
DK (1) DK1804836T3 (de)
MX (1) MX2007003522A (de)
NI (1) NI200700081A (de)
SG (1) SG155257A1 (de)
WO (1) WO2006034507A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
JP5270161B2 (ja) 2004-09-24 2013-08-21 ベス イスラエル デアコネス メディカル センター 妊娠合併症を診断および処置する方法
CA2591142A1 (en) * 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center, Inc. Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
AU2006226891A1 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
CN101517078A (zh) * 2006-05-31 2009-08-26 貝丝以色列女执事医疗中心 诊断和治疗妊娠并发症的方法
WO2007143023A1 (en) * 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
EP1936380A1 (de) * 2006-12-21 2008-06-25 F. Hoffmann-Roche AG Plazentaler Wachstumsfaktor, lösliches FLT1 und Endoglin sind Prädiktoren für den angiogenischen Zustand einer Person
GB0703683D0 (en) 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009144229A1 (en) * 2008-05-27 2009-12-03 F. Hoffmann-La Roche Ag Method for risk reduction in glycemic control
AU2010240781B2 (en) 2009-04-23 2015-05-28 Wallac Oy Methods for determining maternal health risks
CA2799227C (en) 2010-05-14 2020-06-16 Beth Israel Deaconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy
CA2826563C (en) 2011-02-07 2020-10-20 Paul Kussie Methods and systems for treating eclampsia and pre-eclampsia
WO2013000992A1 (en) 2011-06-28 2013-01-03 Vitateq Biotechnology Gmbh Method for diagnosing preeclampsia
WO2013019805A1 (en) 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
EP2776839B1 (de) * 2011-11-09 2017-08-30 Roche Diagnostics GmbH Dynamik des sflt-1 oder endoglin/plgf-verthältnisses als indikator für drohende präeklampsie und/oder drohendes hellp-syndrom
US10670610B2 (en) * 2012-06-15 2020-06-02 Wayne State University Biomarker test for prediction or early detection of preeclampsia and/or HELLP syndrome
SG11201407667UA (en) * 2012-06-27 2015-02-27 Hoffmann La Roche MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
EP2706359A1 (de) 2012-09-07 2014-03-12 Roche Diagniostics GmbH Mittel und Verfahren zur Anwendung des sFlt-1/PlGF- oder Endoglin/PlGF-Verhältnisses zum Ausschließen des Ausbruchs von Präeklampsie innerhalb eines bestimmten Zeitraums
JP2015522258A (ja) * 2012-09-10 2015-08-06 ウェーン ステイト ユニヴァーシティＷａｙｎｅ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 子癇前症及び／またはｈｅｌｌｐ症候群の予測または早期検出のバイオマーカー検査
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
ES2670544T3 (es) * 2013-02-28 2018-05-30 The Chinese University Of Hong Kong Análisis de transcriptoma de plasma materno por secuenciación masiva en paralelo de ARN
JP6519842B2 (ja) * 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
WO2015110624A1 (en) 2014-01-24 2015-07-30 Roche Diagnostics Gmbh Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
WO2016057993A1 (en) * 2014-10-10 2016-04-14 Wayne State University Methods and compositions relating to assays of fetal extravillous trophoblast cells
PL3322985T3 (pl) * 2015-07-15 2022-02-21 GestVision, Inc. Urządzenie do wykrywania nieprawidłowo pofałdowanych białek i sposoby jego wykorzystania
RU2607029C1 (ru) * 2015-10-20 2017-01-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ" Минздрава России ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus L. - EN-4C9 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ПРОТИВ ЭНДОГЛИНА (CD105) ЧЕЛОВЕКА
US20190128895A1 (en) * 2016-04-20 2019-05-02 Ldx Prognostics Limited Co. Methods and compositions for prognosing preterm birth
WO2017197573A1 (en) 2016-05-17 2017-11-23 Ldx Prognostics Limited Co. Methods and compositions for providing preeclampsia assessment
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP4717319A3 (de) * 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Verfahren zur behandlung von morbus fabry bei schwangeren patienten
BR112020017626A2 (pt) * 2018-02-28 2020-12-22 Pharming Intellectual Property B.V. Tratamento e prevenção de pré-eclâmpsia
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
US12599323B2 (en) 2019-12-13 2026-04-14 Aggamin, LLC Methods and systems for treating pregnancy-related hypertensive disorders comprising anti-sEng and anti-sFlt-1 antibodies
WO2021118955A1 (en) * 2019-12-13 2021-06-17 Aggamin Llc Methods and systems for treating or preventing pregnancy-related hypertensive disorders
US12436155B2 (en) 2020-04-16 2025-10-07 Kalia Health, Inc. Preeclampsia screening device and methods measuring activin and/or inhibin A
EP3900733A1 (de) 2020-04-24 2021-10-27 Derma Innovate S.L. Src-kinase-aktivatoren und eng-funktion-inhibitoren als verstärker der hautomöostase/-regenerierung und des haarwachstums
AU2021276336A1 (en) * 2020-05-18 2022-11-24 Cedars-Sinai Medical Center Devices, assays and methods of testing preeclampsia
CN115873943B (zh) * 2023-02-13 2024-03-29 山东大学 骨形态发生蛋白2在子痫前期诊断、预防和治疗中的应用
WO2025147624A1 (en) * 2024-01-03 2025-07-10 Cedars-Sinai Medical Center Devices, assays and methods of testing preeclampsia
CN118340868A (zh) * 2024-05-11 2024-07-16 山东大学 骨形态发生蛋白7在子痫前期预防和/或治疗中的应用
WO2026033033A1 (en) * 2024-08-07 2026-02-12 Beech Biotech Sa Compositions and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) * 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (de) 1991-06-14 2003-11-26 Genentech, Inc. Humanisierter Heregulin Antikörper
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
AU691297B2 (en) 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
US5641636A (en) * 1994-05-20 1997-06-24 University Of Pennsylvania Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity
US6613757B1 (en) 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
CA2205964A1 (en) * 1994-11-29 1996-06-06 Douglas A. Marchuk Diagnosis of and therapy for hereditary haemorrhagic telangiectasia
IT1271593B (it) 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
GB9512994D0 (en) * 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
EP0938505B1 (de) * 1996-05-31 2002-03-06 Health Research, Inc. Monoklonale Antikörper gegen Endoglin und ihre Verwendung in der anti-Angiogenese-Therapie
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
AU5331298A (en) 1996-12-23 1998-07-17 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
WO1998040747A1 (en) * 1997-03-07 1998-09-17 Mount Sinai Hospital Corporation Methods to diagnose a required regulation of trophoblast invasion
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20030114407A1 (en) * 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6245577B1 (en) * 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
EP1016726A1 (de) 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
JP2002541829A (ja) * 1999-04-16 2002-12-10 イエール・ユニバーシテイ 遺伝子治療および治療的スクリーニングに有用なｅＮＯＳ変異体
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AR031129A1 (es) * 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
GB0026823D0 (en) * 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (en) * 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Antisense modulation of recql5 expression
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20050043227A1 (en) * 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP5650876B2 (ja) * 2002-07-19 2015-01-07 ベス・イスラエル・ディーコニス・メディカル・センター 子癇前症または子癇の診断方法および治療方法
DE10333105B3 (de) 2003-07-21 2005-05-25 OCé PRINTING SYSTEMS GMBH Einrichtung zur Einstellung der Spannung einer Materialbahn, die durch eine die Materialbahn bearbeitende Prozessstation bewegt wird
CA2539430C (en) * 2003-09-23 2015-03-17 The General Hospital Corporation Screening for gestational disorders with sex hormone binding globulin as biomarker
US20050181451A1 (en) 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
JP5270161B2 (ja) 2004-09-24 2013-08-21 ベス イスラエル デアコネス メディカル センター 妊娠合併症を診断および処置する方法
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
CA2591142A1 (en) 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center, Inc. Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
EP1839056B1 (de) 2004-12-21 2011-08-03 Yale University Präeklampsie-diagnose
CN101517078A (zh) 2006-05-31 2009-08-26 貝丝以色列女执事医疗中心 诊断和治疗妊娠并发症的方法
US20100247650A1 (en) 2009-03-31 2010-09-30 Smith Henry J Treatment for pre-eclampsia in pregnant women using targeted apheresis

Also Published As

Publication number Publication date
WO2006034507A2 (en) 2006-03-30
CA2581336C (en) 2022-10-04
US20060067937A1 (en) 2006-03-30
EP2347765B1 (de) 2014-01-22
CN101065667B (zh) 2013-09-04
US20170072018A1 (en) 2017-03-16
WO2006034507A3 (en) 2007-06-14
SG155257A1 (en) 2009-09-30
DK1804836T3 (da) 2011-01-24
US10413591B2 (en) 2019-09-17
HK1107592A1 (en) 2008-04-11
KR101356894B1 (ko) 2014-02-06
NI200700081A (es) 2008-05-13
JP2008514631A (ja) 2008-05-08
EP1804836B1 (de) 2010-11-17
BRPI0515884A (pt) 2008-08-12
EP1804836A4 (de) 2008-07-09
JP2015057426A (ja) 2015-03-26
HK1160388A1 (en) 2012-08-17
KR20130119506A (ko) 2013-10-31
EP2347765A1 (de) 2011-07-27
JP5715589B2 (ja) 2015-05-07
CA2581336A1 (en) 2006-03-30
JP5270161B2 (ja) 2013-08-21
AU2005286626B2 (en) 2012-11-08
EP1804836A2 (de) 2007-07-11
KR20070059174A (ko) 2007-06-11
MX2007003522A (es) 2007-06-11
US20110243956A1 (en) 2011-10-06
CN101065667A (zh) 2007-10-31
JP2012211131A (ja) 2012-11-01
DE602005024850D1 (de) 2010-12-30
AU2005286626A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
DE602005024850D1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
EA200700708A1 (ru) Мемантин для лечения расстройств поведения детского возраста
ATE503563T1 (de) Blockverhältnisverbesserendes mittel für permeable membran, verfahren zur blockverhältnisverbesserung, permebale membran und wasserbehandlungsverfahren
ATE537445T1 (de) Screening-verfahren
EP2029743A4 (de) Verfahren zur diagnose und behandlung von schwangerschaftskomplikationen
TW200626900A (en) Wnt proteins and detection and treatment of cancer
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
ATE485047T1 (de) Verwendung eines wachstumsstimulierenden proteins
DE60328198D1 (de) Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE520987T1 (de) Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum
ATE480641T1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
DE602006013143D1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
EP1896581A4 (de) Substanzen, zusammensetzungen und verfahren zur vorbeugung und behandlung immunvermittelter entzündungskrankheiten
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
ATE396200T1 (de) Reagenzien zur diagnose und behandlung von latexallergie und verfahren zu ihrer herstellung
WO2007047634A3 (en) Method to diagnose, predict treatment response and develop treatments for psychiatric disorders using markers
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
ATE363075T1 (de) Verfahren zur diagnose und behandlung von metastasen und dafür nützliche zusammensetzung
ATE516813T1 (de) Verfahren und verbindungen zur behandlung von diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties